Daratumumab plus Bortezomib/ Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study

Sonneveld P., Moreau P., Dimopoulos M. A., Quach H., Ho P. J., BEKSAÇ M., ...Daha Fazla

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024 (SCI-Expanded, Scopus)

• Yayın Türü: Makale / Özet
• Basım Tarihi: 2024
• Dergi Adı: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
• Ankara Üniversitesi Adresli: Evet